TB-500 dose range
The amounts people commonly use, from the low end to the high end, with syringe units, schedule and half-life. The 10 published studies are one click away.
Human trials Repair Also called Thymosin Beta-4
Common use ranges
From published clinic and pharmacy protocols. No drug label exists. Good agreement on 2 to 2.5 mg twice weekly loading and about 2 mg weekly maintenance. The injury tier comes from one telehealth source only.
- Half-life
- about 0.5 to 2 hours, measured for full thymosin beta-4
- How it is taken
- Subcutaneous injection, usually in the belly
- How long people use it
- About 8 to 12 weeks in total (4 to 6 weeks loading, then maintenance), then a 4 to 8 week break before reassessing.
- Mixing used for the units
- 10 mg vial + 2 mL water. 1 unit on a U-100 insulin syringe = 50 mcg.
Pick your vial size and how much water you add. The units below change to match.
10 mg vial + 2 mL water: 1 unit = 50 mcg
| Tier | Each dose | Syringe units10 mg vial + 2 mL water | How often | Schedule | Vial lastsat this tier |
|---|---|---|---|---|---|
| Starting [1] | 1 mg | 20 units 0.20 mL | 2x a week | Gentler on-ramp: 1 mg twice a week for the first two weeks, then move to the loading dose | about 5 weeks |
| Loading [2] | 2 mg | 40 units 0.40 mL | 2x a week | 2 to 2.5 mg twice a week, spaced 3 to 4 days apart (like Monday and Thursday), for 4 to 6 weeks | 17 days |
| Injury (reported) [3] | 5 mg | 100 units 1.00 mL | 2x a week | Less common heavier loading: up to 5 mg twice a week for the first two weeks only, then the normal loading dose | 7 days |
| Maintenance [4] | 2 mg | 40 units 0.40 mL | once a week | 2 mg once a week (some go once every two weeks) for 4 to 12 weeks after loading | about 5 weeks |
Good to know
- The loading then maintenance shape is near universal. The exact numbers vary by source.
- Some prescribers shorten loading to 4 weeks for a defined soft tissue strain and stretch it to 8 weeks for chronic problems.
- Most practitioners stay at 2 to 5 mg per shot. Higher has not been studied.
- Banned by WADA for tested athletes.
Sources for these amounts
- Starting: Form Blends, TB-500 Dosage Protocols
- Loading: Form Blends, TB-500 Dosage Protocols · Form Blends, TB-500 Dosage Guide
- Injury (reported): Form Blends, TB-500 Dosage Guide (higher acute injury loading, says it needs direct physician oversight)
- Maintenance: Form Blends, TB-500 Dosage Protocols · Form Blends, TB-500 Dosage Guide · Bio Hack Lab, TB-500 5mg Dosage Guide (1 to 2 times weekly)
How long people use it: Form Blends, TB-500 Dosage Protocols · Form Blends, TB-500 Dosage Guide · Bio Hack Lab, TB-500 5mg Dosage Guide
Half-life: Phase 1 of recombinant thymosin beta-4 in healthy Chinese volunteers, 2021 · Ruff et al 2010, Ann N Y Acad Sci, IV thymosin beta-4 in healthy volunteers (half-life rose with dose)
Take the TB-500 chart with you
Get a one-page printable chart for TB-500, with the syringe units for each vial and water mix. We can also email you when a new TB-500 study is published.
This page shows what labels, clinics and users report, and what studies gave. It is not medical advice and not a recommendation for anyone. Many of these compounds are not approved for human use. Check your own medicines and lab work with a licensed clinician before using anything.
See the science: 10 published studies
Amounts given to people in studies
How it was given: Into a vein (IV). Eye drop trials used a 0.1% solution.
Human data is for full-length Thymosin Beta-4. No human study of the short Ac-LKKTETQ fragment was found.
Amounts given to animals in studies
Read this first. The 1,260 mg figure is printed that way in the study abstract. It is far above every other human figure, so treat it as unconfirmed until checked against the full paper.
Every study used for this page
Proof grade: Human trials. Tested in randomized human trials. Amounts are quoted as each study reported them. Where the abstract does not state an amount, the row says so.
| Study | Who was studied | Amount given, as reported | Route | How often | How long | What the authors reported |
|---|---|---|---|---|---|---|
| PMID 34346165NL005 recombinant human Tb4, phase I2021 | Human, 54 healthy (single), 30 (multiple) | Single: 0.05, 0.25, 0.5, 2.0, 5.0, 12.5, 25.0 mcg/kg. Multiple: 0.5, 2.0, 5.0 mcg/kg | IV | Single, or once daily | 10 days, observed 28 days | No dose-limiting toxicity or serious AEs, dose-proportional PK |
| PMID 20536472Ruff et al., Ann NY Acad Sci 2010 | Human, 4 cohorts x 10 healthy | 42, 140, 420, 1260 mg | IV | Single, then same dose daily | 14 days | Well tolerated, no dose-limiting toxicity |
| PMID 41229390rhTB4 STEMI, 2025 | Mice, and 96 STEMI patients (43 rhTB4) | Not stated in the abstract | Not in abstract | First dose within 8 h after PCI | 7-day treatment in mice, 90-day follow-up | Smaller infarct area vs placebo at 90 days. Dose not verified |
| PMID 26056426RGN-259, phase II dry eye2015 | Human, 72 | 0.1% Tb4 ophthalmic solution (concentration) | Topical eye drop | Not in abstract | 28 days | Discomfort score down 27% vs placebo at day 28 |
| PMID 25826322RGN-259, severe dry eye2015 | Human, 9 patients (12 eyes active, 6 vehicle) | 0.1% RGN-259 (concentration) | Topical eye drop | 6 times daily | 28 days treatment, 56-day study | 35.1% less discomfort, 59.1% less corneal staining vs vehicle |
| PMID 17495250venous ulcer, 2007 | Human, design report, 21 enrolled | Dose-escalation, doses NOT STATED in abstract | Topical | Not stated | 84 days planned | Design and early report only, no efficacy data |
| PMID 25060418Morris et al., J Neurol Sci 2014 | Rat Wistar male, 10 per group, embolic stroke | 2, 12, 18 mg/kg | IP | 24 h after MCAo, then every 3 days for 4 more doses | 56 days | Benefit at 2 and 12 mg/kg, none at 18 mg/kg. Estimated optimal 3.75 mg/kg |
| PMID 28864242aged-rat stroke, 2017 | Rat, aged 18-21 mo, 23 total (12 control, 11 Tb4) | 12 mg/kg | Not stated in abstract | 24 h after MCAo, then every 3 days x4 | 56 days | Infarct volume reduced, no functional gain |
| PMID 25042765fracture healing, 2014 | Mouse (n not in abstract) | 6 mg/kg | IP | Schedule not in abstract | To day 21 | 41% higher peak force to failure |
| PMID 23320620bleomycin lung, 2013 | Mouse C57BL/6 (n not in abstract) | 6 mg/kg | IP | Day of bleomycin plus 2 more doses | Not in abstract | Less weight loss, higher survival |
How to read the study numbers
- One study, one group. Each figure is what one team chose for its own participants or animals.
- Route matters. An amount given into a vein (IV) is not the same as the same amount under the skin, in the nose or by mouth.
- Animals are not small people. An animal amount is shown as the study gave it. It is not a human amount.
- Short studies. Many studies ran days or weeks. They do not show what happens over longer use.
Common questions
What amounts of TB-500 were used in human studies?
In the studies listed here, people were given from 0.05 mcg/kg IV up to 1,260 mg IV (phase 1 safety study, as printed). The amount used most often was 0.5 to 5 mcg/kg IV daily for 10 days. These are what study teams chose for their participants under supervision.
Where do these TB-500 numbers come from?
From 10 published studies, each linked to its PubMed or ClinicalTrials.gov record. Every figure was checked against the study abstract or its open full text. Proof grade: Human trials.
How long does TB-500 stay in the body?
Its half-life is about 0.5 to 2 hours, measured for full thymosin beta-4 in people. Half-life is how long it takes for half of a dose to leave the blood. The effect can last longer than that.
Is this a recommendation for how much TB-500 to use?
No. This page shows the amounts reported by drug labels, clinics and users, next to what researchers gave in studies. It is not medical advice and not a recommendation for anyone. Talk to a licensed clinician before using any of it.